In this study, patients with EGFR-sensitive mutations were more sensitive to immunotherapy, suggesting a potential benefit for EGFR mutation-positive NSCLC from ICIs in a clinical setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.